Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)
Public ClinicalTrials.gov record NCT06215586. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Preserved Ejection Fraction
Study identification
- NCT ID
- NCT06215586
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Cardurion Pharmaceuticals, Inc.
- Industry
- Enrollment
- 303 participants
Conditions and interventions
Conditions
Interventions
- Tovinontrine (CRD-750 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 12, 2024
- Primary completion
- Sep 1, 2025
- Completion
- Sep 1, 2025
- Last update posted
- Nov 16, 2025
2024 – 2025
United States locations
- U.S. sites
- 22
- U.S. states
- 15
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cardurion Investigative Site | Birmingham | Alabama | 35233 | — |
| Cardurion Investigative Site | Little Rock | Arkansas | 72204 | — |
| Cardurion Investigative Site | Orange | California | 92868 | — |
| Cardurion Investigative Site | Torrance | California | 90502 | — |
| Cardurion Investigative Site | Van Nuys | California | 91405 | — |
| Cardurion Investigative Site | Jacksonville | Florida | 32216 | — |
| Cardurion Investigative Site | Miami | Florida | 33137 | — |
| Cardurion Investigative Site | Hazel Crest | Illinois | 60429 | — |
| Cardurion Investigative Site | Peoria | Illinois | 61636 | — |
| Cardurion Investigative Site | Alexandria | Louisiana | 71301 | — |
| Cardurion Investigative Site | Covington | Louisiana | 70433 | — |
| Cardurion Investigative Site | St Louis | Missouri | 63110 | — |
| Cardurion Investigative Site | Buffalo | New York | 14215 | — |
| Cardurion Investigative Site | New York | New York | 10019 | — |
| Cardurion Investigative Site | Cleveland | Ohio | 44195 | — |
| Cardurion Investigative Site | Oklahoma City | Oklahoma | 73135 | — |
| Cardurion Investigative Site | Portland | Oregon | 97225 | — |
| Cardurion Investigative Site | Rapid City | South Dakota | 57701 | — |
| Cardurion Investigative Site | Nashville | Tennessee | 37232-7601 | — |
| Cardurion Investigative Site | Dallas | Texas | 75246 | — |
| Cardurion Investigative Site | McKinney | Texas | 75069 | — |
| Cardurion Investigative Site | Burlington | Vermont | 05401 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 62 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06215586, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 16, 2025 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06215586 live on ClinicalTrials.gov.